Napazimone

N/A

Report date: 2026/04/16 20:00:17
NME

Base Information

Drug NameNapazimone
Drug Alias NameNQO1 substrate KTG Life SciencesKL-1333
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNAD(Nicotinamide adenine dinucleotide) modulators
TargetsNAD(Nicotinamide adenine dinucleotide)
Therapy Area/IndicationsMitochondrial DiseasesMELAS SyndromeMitochondrial Myopathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[10
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
China Registration ClassN/A

Develop Information

Inactive CompaniesYungjin Pharm Co Ltd
Active IndicationsMitochondrial Diseases
Inactive IndicationsMELAS SyndromeMitochondrial Myopathies

Other Information

ATC CodeN/A
Related LinksN/A